This document serves as an erratum for the research paper "Balancing efficacy and safety of doxorubicin-loaded albumin nanoparticles utilizing pH-sensitive doxorubicin-fatty acid prodrugs," originally published in Nano Research (2024). This update corrects a data visualization error in the original study regarding the cellular uptake of pH-sensitive doxorubicin prodrugs.
Introduction
The original research addresses a fundamental challenge in oncology: the targeted delivery of doxorubicin (DOX) to tumor cells while sparing healthy tissue. The authors developed a library of albumin nanoparticles (ANPs) loaded with pH-sensitive DOX-fatty acid prodrugs. By varying the fatty acid chain length (C10 to C26), the study aimed to identify formulations that remain stable in systemic circulation (pH 7.4) but release the active drug in the acidic tumor microenvironment.
Methodology
The study employed a rigorous experimental framework to validate the performance of these nanoparticles:
- Confocal Laser Scanning Microscopy (CLSM): Used to track the spatial and temporal uptake of nanoparticles in 4T1 mouse breast cancer cells. Nuclei were stained with Hoechst (blue), while DOX provided intrinsic red fluorescence.
- Cytotoxicity Assays: The researchers determined IC50 values (the concentration required to inhibit 50% of cell growth) to quantify the potency of different formulations across various cell lines.
- Cell Models: Performance was evaluated in 4T1 (breast cancer), KB (folate receptor-positive), Hepa 1-6 (liver cancer), and L02 (normal liver) cells.
Key Insights
The corrected data clarifies how fatty acid chain length influences drug behavior. Confocal imaging confirms that the albumin nanoparticles are successfully internalized by cells, with red fluorescence increasing over time (0.5 to 4 hours).
Quantitative analysis revealed that chain length significantly impacts toxicity. Generally, increasing the chain length leads to lower IC50 values in cancer cells, suggesting that longer chains enhance the stability or cellular internalization of the prodrug. Crucially, the formulations demonstrated selectivity; IC50 values in healthy L02 liver cells were significantly higher (often >5000 nM) than in cancer lines, indicating a favorable safety profile.
Results and Correction
The erratum specifically addresses a clerical error in Figure 4(a), where confocal images for the DOX-C22 and DOX-C26 groups at the 4-hour mark were swapped. The corrected figure now accurately aligns the visual evidence of drug accumulation with the corresponding nanoparticle formulations.
As shown in the cytotoxicity data for KB cells, the DOX-C26 ANPs demonstrated superior potency compared to shorter-chain variants. Statistical analysis (two-tailed Student’s t-tests) confirmed that these differences in efficacy are significant, supporting the conclusion that optimizing the hydrophobic tail of the prodrug is vital for maximizing therapeutic impact.
Conclusion
While this erratum corrects a visual transposition in the original manuscript, the core findings of the study remain robust. The development of pH-sensitive albumin nanoparticles with optimized fatty acid chains represents a promising strategy for improving the therapeutic index of doxorubicin.
Summary updated